Site-specific gene correction of a point mutation in human iPS cells derived from an adult patient with sickle cell disease. - Wikidata - wikimedia - TriplyDB

Site-specific gene correction of a point mutation in human iPS cells derived from an adult patient with sickle cell disease.

Site-specific gene correction of a point mutation in human iPS cells derived from an adult patient with sickle cell disease.

http://www.wikidata.org/entity/Q35525329

about

RNA-guided human genome engineering via Cas9 Site-Specific Genome Engineering in Human Pluripotent Stem Cells Human induced pluripotent stem cells for monogenic disease modelling and therapy Customizing the genome as therapy for the β-hemoglobinopathies Genome-editing Technologies for Gene and Cell Therapy An Overview of Direct Somatic Reprogramming: The Ins and Outs of iPSCs Neuroprotective therapies in glaucoma: II. Genetic nanotechnology tools Dissecting diabetes/metabolic disease mechanisms using pluripotent stem cells and genome editing tools Progress and obstacles towards generating hematopoietic stem cells from pluripotent stem cells The potential of stem cells as an in vitro source of red blood cells for transfusion Sickle cell disease in children Disease modeling and cell based therapy with iPSC: future therapeutic option with fast and safe application Gene therapy on the move Manufacturing blood ex vivo: a futuristic approach to deal with the supply and safety concerns Induced pluripotent stem cells in hematology: current and future applications Low-Dose Irradiation Enhances Gene Targeting in Human Pluripotent Stem Cells β-Globin sleeping beauty transposon reduces red blood cell sickling in a patient-derived CD34(+)-based in vitro model Transcription activator-like effector nuclease (TALEN)-mediated CLYBL targeting enables enhanced transgene expression and one-step generation of dual reporter human induced pluripotent stem cell (iPSC) and neural stem cell (NSC) lines.The potential of gene therapy approaches for the treatment of hemoglobinopathies: achievements and challenges Gene therapy for hemophilia ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering Congenital amegakaryocytic thrombocytopenia iPS cells exhibit defective MPL-mediated signaling.Integration-defective lentiviral vector mediates efficient gene editing through homology-directed repair in human embryonic stem cells Enhancement of β-Globin Gene Expression in Thalassemic IVS2-654 Induced Pluripotent Stem Cell-Derived Erythroid Cells by Modified U7 snRNA.Differential sensitivity to JAK inhibitory drugs by isogenic human erythroblasts and hematopoietic progenitors generated from patient-specific induced pluripotent stem cells Induced Pluripotent Stem Cells: Global Research Trends.Differentiation of neuron-like cells from mouse parthenogenetic embryonic stem cells.Seamless gene correction of β-thalassemia mutations in patient-specific iPSCs using CRISPR/Cas9 and piggyBac.Human induced pluripotent stem cells can reach complete terminal maturation: in vivo and in vitro evidence in the erythropoietic differentiation model.CRISPR/Cas9 for genome editing: progress, implications and challenges.Investigating human disease using stem cell models.Genomic editing tools to model human diseases with isogenic pluripotent stem cells.Multiplex CRISPR/Cas9-based genome engineering from a single lentiviral vector.Induced Pluripotent Stem Cells Meet Genome Editing Efficient drug screening and gene correction for treating liver disease using patient-specific stem cells.Stability of zinc finger nuclease protein is enhanced by the proteasome inhibitor MG132.International regulatory landscape and integration of corrective genome editing into in vitro fertilization.Direct cloning of isogenic murine DNA in yeast and relevance of isogenicity for targeting in embryonic stem cells.Generation of 3D skin equivalents fully reconstituted from human induced pluripotent stem cells (iPSCs).Nuclease-mediated gene editing by homologous recombination of the human globin locus.

P2860

Q24598394-D47C8D27-6D86-4F85-9016-4631C02B18B2 Q26747006-7EED1C33-ACDB-427A-9929-C4DF027190FE Q26750393-537DA05D-813B-4A4A-9A66-E4DC903C55BE Q26751061-C06C16A8-82D4-48D5-B970-EFF654DCBA23 Q26769662-B8D95DF8-5DC8-4535-84E9-232C41187F04 Q26775122-80262511-D202-434C-8180-FA47C8760C2C Q26777286-936536EA-C349-4855-A430-97048A802D5B Q26785684-D7C99A02-84C3-4CE2-ADEF-E0CEBC851298 Q26824479-D85C6713-132D-4913-9D2D-5C53D3DBE258 Q26852096-84D6BA9C-A38D-468F-924F-A4D45BB307B6 Q26864582-75E370AD-D53A-4C26-8A1B-3AAF8173FCB1 Q26866409-49D82342-03A7-46BB-9FB5-BC143B3B7E36 Q27007012-2571F1D5-DA65-48A9-9E85-5776B6E5CC07 Q27007110-28E8B807-BBA7-4EED-8225-B6E03987843B Q27016090-C02C5AAD-01EC-4CCD-9DD6-9627E5B2209A Q27301084-6EE9068F-3E60-4FEF-A0B4-80ADF5981317 Q27301943-526F71A4-142C-4E99-A710-06944220E6B5 Q27318385-6F6FA7EF-1D15-46EA-BF66-8BC6534F4298 Q28077484-047E3692-36F9-4C19-BFA5-8501CA72428D Q28081911-E0205A67-719F-4500-8CA4-4C47AF396BFD Q29615505-1C2499FB-3989-487A-9E49-193FB5B13F2B Q33409483-F4ED669E-5972-4451-A4C7-A38D3AAD4CA8 Q33558379-988271AB-E8B7-4D28-8DDF-984A081BC2D1 Q33722582-E7D75782-2B70-48FA-9767-98A98683E1E1 Q33894805-2FF185F0-95B0-462A-8CA9-8B5669C91061 Q33914515-58E04448-D006-4A5E-B4C0-511FE4F65AB8 Q33936482-80730962-3348-4C03-B92F-D1C2D57F4189 Q34153816-4BC1AC4C-5274-4411-8C25-9681D27F3CF4 Q34284032-4899C35C-C49D-46B0-ADAD-990EE457DC3A Q34411191-88C5B258-EBD9-402C-90B1-AB66CCDF89CA Q34431170-AC894B40-A812-430E-B13C-5603905AB6A3 Q34437293-B281A9DD-B958-47D3-9533-2F38299A1A97 Q34509983-8452D9B3-3A44-46FA-9E03-71583A04F981 Q34525438-2D29F211-BF9B-4559-8C15-D46F86E25E8B Q34550486-34D4EEEE-8E8F-4606-9514-8E4988C7F95B Q34568279-B41245C8-D986-4228-8EFD-161EB079731C Q34611496-9041953B-99F4-471D-B369-709CCCD86142 Q34994552-EA7060F6-7EA8-4A0E-8016-F5F734792258 Q35023324-07D6DFE6-28C9-441F-959C-8938DB104617 Q35025959-8592D421-4C6E-4822-960C-90D350BEFF1C

P2860

Site-specific gene correction of a point mutation in human iPS cells derived from an adult patient with sickle cell disease.

http://www.wikidata.org/entity/Q35525329

description

2011 nî lūn-bûn

@nan

2011 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Site-specific gene correction ...... ient with sickle cell disease.

@ast

Site-specific gene correction ...... ient with sickle cell disease.

@en

type

label

Site-specific gene correction ...... ient with sickle cell disease.

@ast

Site-specific gene correction ...... ient with sickle cell disease.

@en

prefLabel

Site-specific gene correction ...... ient with sickle cell disease.

@ast

Site-specific gene correction ...... ient with sickle cell disease.

@en

P1433

Q35525329-45E934BF-1457-4D8D-9CB3-D6EE318A5109

P1476

Q35525329-84ADD1B6-BC86-4A1B-B80B-4B6C6E0859EA

P2093

Q35525329-332F3FFD-0BA7-425E-881E-D9FFA209599F

Q35525329-5FB4978E-158F-486C-8C8B-6CDF68A99D12

Q35525329-7BC11C79-B47F-43F2-9234-602BCA360EF0

Q35525329-E333F7FD-5790-45FA-B1AC-85B6FF04A89F

P2860

Q35525329-136B6D3C-FB71-4A10-A2E9-881CC572F7F0

Q35525329-1F58A3A0-C0FA-4C96-894A-28922F61D9AC

Q35525329-232477A3-856E-4554-97CE-AB6ECB015885

Q35525329-2C1BF228-DA5F-414E-B9A3-DD1A8F3D4F66

Q35525329-3458339F-7F80-4F07-813E-BEE91D8AF379

Q35525329-349DEAC0-1F55-422F-9110-B84241FD8581

Q35525329-3A994C9D-0785-4FFB-BCD0-CCFD080E99E4

Q35525329-3AAFD7C0-F4FD-45B3-99F9-2BEA67FD83F7

Q35525329-3F4CD43F-2996-4A8E-8A4B-D293DC1C4CDC

Q35525329-449E1978-14CD-4CBF-BD51-ECB210E53055

P304

Q35525329-E561ED08-7782-4291-A682-8FE720866E60

P31

Q35525329-7B6F907A-3235-49B4-8421-760BF6282311

P356

Q35525329-69FD41B0-171C-46D1-BF90-20E053DFD0CA

P407

Q35525329-B5E0A6E6-8B05-474B-9125-FF2C62AF7464

P433

Q35525329-AF9CDFE5-32CE-4DF1-9903-8A97B826A946

P478

Q35525329-07277499-981D-4207-B8B8-0054ECCF3FD9

P50

Q35525329-13B3062C-4FA3-46E2-9EBA-33AA03F843DB

P577

Q35525329-96F0A943-A317-4024-800A-A7AA8D62D551

P5875

Q35525329-B928D620-653A-4098-9265-B7F26FBB28CD

P698

Q35525329-4A52EDAF-D15B-4FC9-9F30-4014B242E3E1

P921

Q35525329-7C3926E2-7EDC-4129-AE94-2DEA06C86106

Q35525329-C05F2429-D8F3-490F-9727-D54541F8BE9A

P932

Q35525329-EA8B0EC4-A120-43FF-8B3F-757884580458

P356

BLOOD-2011-02-335554

P1433

P1476

Site-specific gene correction ...... ient with sickle cell disease.

@en

P2093

Jizhong Zou

http://www.w3.org/2001/XMLSchema#string

Prashant Mali

http://www.w3.org/2001/XMLSchema#string

Sarah N Dowey

http://www.w3.org/2001/XMLSchema#string

Xiaosong Huang

http://www.w3.org/2001/XMLSchema#string

P2860

Insertion of DNA sequences into the human chromosomal beta-globin locus by homologous recombination

A TALE nuclease architecture for efficient genome editing

Treatment of sickle cell anemia mouse model with iPS cells generated from autologous skin

Efficient targeting of expressed and silent genes in human ESCs and iPSCs using zinc-finger nucleases

Disease-corrected haematopoietic progenitors from Fanconi anaemia induced pluripotent stem cells.

Human-induced pluripotent stem cells from blood cells of healthy donors and patients with acquired blood disorders

A hyperactive piggyBac transposase for mammalian applications

Engineering of human pluripotent stem cells by AAV-mediated gene targeting.

Autologous blood cell therapies from pluripotent stem cells.

Selection-free zinc-finger-nuclease engineering by context-dependent assembly (CoDA)

P304

4599-4608

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2011-02-335554

http://www.w3.org/2001/XMLSchema#string

P407

P433

17

http://www.w3.org/2001/XMLSchema#string

P478

118

http://www.w3.org/2001/XMLSchema#string

P50

P577

2011-08-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51608749

http://www.w3.org/2001/XMLSchema#string

P698

21881051

http://www.w3.org/2001/XMLSchema#string

P921

sickle-cell disease

P932

3208277

http://www.w3.org/2001/XMLSchema#string